JAZZ Jazz Pharmaceuticals plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JAZZ

Price (delayed)

$141.28

Market cap

$8.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.58

Enterprise value

$13.86B

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration ...

Highlights
The company's EPS rose by 35% YoY
Jazz Pharmaceuticals's net income has increased by 32% YoY
Jazz Pharmaceuticals's equity has decreased by 22% YoY but it has increased by 12% from the previous quarter
Jazz Pharmaceuticals's quick ratio has increased by 15% YoY but it has decreased by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: TEVA ABC

Key stats

What are the main financial stats of JAZZ
Market
Shares outstanding
63.33M
Market cap
$8.95B
Enterprise value
$13.86B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.88
Price to sales (P/S)
2.41
EV/EBIT
N/A
EV/EBITDA
25.91
EV/Sales
3.79
Earnings
Revenue
$3.66B
EBIT
-$94.46M
EBITDA
$535.01M
Free cash flow
$1.24B
Per share
EPS
-$3.58
Free cash flow per share
$19.87
Book value per share
$49.01
Revenue per share
$58.51
TBVPS
$53.54
Balance sheet
Total assets
$10.84B
Total liabilities
$7.75B
Debt
$5.8B
Equity
$3.09B
Working capital
$1.67B
Liquidity
Debt to equity
1.88
Current ratio
2.79
Quick ratio
1.64
Net debt/EBITDA
9.19
Margins
EBITDA margin
14.6%
Gross margin
85.2%
Net margin
-6.1%
Operating margin
-1.8%
Efficiency
Return on assets
-2%
Return on equity
-7.1%
Return on invested capital
-1.2%
Return on capital employed
-1%
Return on sales
-2.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JAZZ stock price

How has the Jazz Pharmaceuticals stock price performed over time
Intraday
2.79%
1 week
4.54%
1 month
-1.79%
1 year
-11.48%
YTD
-11.32%
QTD
-11.32%

Financial performance

How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.66B
Gross profit
$3.12B
Operating income
-$65.53M
Net income
-$224.06M
Gross margin
85.2%
Net margin
-6.1%
The operating income has dropped by 138% year-on-year and by 127% since the previous quarter
JAZZ's operating margin has dropped by 133% year-on-year and by 126% since the previous quarter
The company's net margin rose by 43% YoY
Jazz Pharmaceuticals's net income has increased by 32% YoY

Growth

What is Jazz Pharmaceuticals's growth rate over time

Valuation

What is Jazz Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.88
P/S
2.41
EV/EBIT
N/A
EV/EBITDA
25.91
EV/Sales
3.79
The company's EPS rose by 35% YoY
Jazz Pharmaceuticals's equity has decreased by 22% YoY but it has increased by 12% from the previous quarter
The price to book (P/B) is 7% higher than the 5-year quarterly average of 2.7 but 4% lower than the last 4 quarters average of 3.0
The price to sales (P/S) is 33% less than the 5-year quarterly average of 3.6 and 11% less than the last 4 quarters average of 2.7
The revenue has grown by 18% YoY and by 2.1% from the previous quarter

Efficiency

How efficient is Jazz Pharmaceuticals business performance
JAZZ's ROIC has shrunk by 152% YoY and by 144% QoQ
The company's return on sales has shrunk by 149% YoY and by 144% QoQ
The company's return on assets rose by 31% YoY
The return on equity has increased by 14% year-on-year

Dividends

What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JAZZ.

Financial health

How did Jazz Pharmaceuticals financials performed over time
The total assets is 40% greater than the total liabilities
Jazz Pharmaceuticals's quick ratio has increased by 15% YoY but it has decreased by 11% from the previous quarter
The company's current ratio fell by 14% YoY and by 12% QoQ
The company's debt is 88% higher than its equity
Jazz Pharmaceuticals's equity has decreased by 22% YoY but it has increased by 12% from the previous quarter
Jazz Pharmaceuticals's debt to equity has increased by 21% YoY but it has decreased by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.